Responding to unprecedented challenges from the pandemic, our industry has witnessed revolutionary ideas and newly established best practices that emerged and transformed the landscape of drug development and commercialization of critical medicines.
New operating paradigms surfaced that removed white space in development timelines. A more resilient approach was adopted in managing supply chains and working with regulators. More companies introduced innovative approaches to advance their clinical pipelines towards licensure. Complimenting these efforts, ISPE continued to push the envelope into ensure we delivered innovative technical resources as well as opportunities to connect, collaborate, and exchange knowledge that ultimately helps propel the pharmaceutical industry forward.
Our more than 20,000 members are at the heart of ISPE supporting the foundation of the pharmaceutical industry. We are a united community working together every day to improve the quality of life for patients and global communities.
